NCT05468359 2026-03-16
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
Clinical Trials
66 trialsNCT05528952 2026-03-16
TERTIO
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT04721132 2026-03-05
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03942328 2026-02-24
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT05488522 2026-02-20
SBRT With Atezo/Bev for HCC
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT05546879 2026-02-10
Liver-NET1
University Hospital, Grenoble
Phase 1 Suspended
NCT07317414 2026-01-05
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT05075993 2025-12-26
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07281664 2025-12-15
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
NCT04862949 2025-12-12
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
CHA University
Completed
NCT07179900 2025-12-11
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT07272265 2025-12-09
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study
Sun Yat-sen University
Phase NA Completed
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07239245 2025-11-25
ATTACH
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05620771 2025-10-20
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Suspended
NCT06789757 2025-10-07
(HCC)
Inova Health Care Services
Phase 2 Recruiting
NCT04857684 2025-10-01
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Massachusetts General Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT04727307 2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2 Recruiting
NCT07192185 2025-09-25
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Sun Yat-sen University
Phase 2 Recruiting
NCT05537402 2025-09-24
LOST-B
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT05197504 2025-09-05
HCC
CHA University
Completed
NCT06294548 2025-08-11
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
University of Alabama at Birmingham
Phase 1/2 Recruiting
NCT05690048 2025-08-06
FLORA
University Hospital Heidelberg
Phase 2 Recruiting
NCT06893887 2025-07-02
ICT-HCC
Nanjing Tianyinshan Hospital
Phase NA Recruiting
NCT07012798 2025-06-10
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04954339 2025-05-31
DYNAMIC
Asan Medical Center
Phase 2 Active not recruiting
NCT05482516 2025-05-22
MRD-GI
Georgetown University
Phase 3 Recruiting
NCT06339424 2025-05-14
PhotonAB
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT05750030 2025-05-06
FMT in IT-refractory HCC - FAB-HCC Pilot Study
Medical University of Vienna
Phase 2 Completed
NCT05448677 2025-04-20
ABE-LIVER
University Hospital, Grenoble
Phase 2 Terminated
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT05992220 2025-02-21
ALERT-HCC
Asan Medical Center
Phase 2 Recruiting
NCT04803994 2025-01-07
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3 Recruiting
NCT06725121 2024-12-16
MacroTrans
University Health Network, Toronto
Phase 1/2 Recruiting
NCT00410956 2024-12-10
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05625893 2024-11-29
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
Samsung Medical Center
Phase 2 Recruiting
NCT06530784 2024-07-31
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT05844046 2024-07-16
MONTBLANC
Ludwig-Maximilians - University of Munich
Phase 2 Recruiting
NCT06405061 2024-07-15
Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT04180072 2024-07-05
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
National Health Research Institutes, Taiwan
Phase NA Active not recruiting
NCT06482801 2024-07-01
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT04541173 2024-06-05
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05970666 2024-02-28
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06265350 2024-02-20
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
Sun Yat-sen University
Phase NA Recruiting
NCT05173298 2024-02-07
HCC
CHA University
Unknown
NCT06199297 2024-01-26
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT06041490 2023-09-18
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT05886257 2023-06-02
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Sun Yat-sen University
Phase 2 Withdrawn
NCT05886465 2023-06-02
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
Phase 2 Unknown